CLINICAL OUTCOMES OF ADULT PATIENTS WITH NON-APL ACUTE MYELOID LEUKEMIA TREATED WITH MODIFIED 2+5 INDUCTION CHEMOTHERAPY: A PROSPECTIVE OBSERVATIONAL STUDY

Background: Modified induction chemotherapy may be considered in acute myeloid leukemia (AML) when treatment tolerance and toxicity are important clinical concerns. This study evaluated one-year clinical outcomes in patients with non-acute promyelocytic leukemia (non-APL) AML treated with modified 2+5 induction chemotherapy. Materials and Methods: This prospective observational cohort study enrolled 38 consecutive patients with non-APL AML who received modified 2+5 induction chemotherapy at Kidwai Memorial Institute of Oncology, Bengaluru, India, with one-year follow-up. The primary outcome was one-year overall survival (OS). Secondary outcomes were complete remission (CR), one-year progression-free survival (PFS), induction mortality, and treatment-related complications. OS and PFS were summarized using the Kaplan-Meier method; exploratory associations were assessed using the chi-square or Fisher's exact test. Results: CR was achieved in 27 patients (71.1%); 5 (13.2%) had refractory disease, and 6 (15.8%) died during induction before marrow assessment. At one year, 21 patients (55.3%) were alive and 16 (42.1%) were alive without a documented PFS event. Febrile neutropenia was the most common complication (89.5%), followed by culture-positive infection (57.9%) and intensive care unit admission (55.3%). Post-induction remission status was associated with one-year survival and PFS status; as a post-treatment variable unavailable in early deaths, it was not interpreted as a baseline prognostic factor. Conclusion: Modified 2+5 induction chemotherapy resulted in a CR rate of 71.1%; 55.3% of patients were alive at one year and 42.1% were alive without a documented PFS event. Given the small, single-center cohort and absence of a comparator arm, these findings should be considered exploratory.

Authors

Publication Details

Journal
Advances in Clinical Medical Research
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24332484
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CLINICAL OUTCOMES OF ADULT PATIENTS WITH NON-APL ACUTE MYELOID LEUKEMIA TREATED WITH MODIFIED 2+5 INDUCTION CHEMOTHERAPY: A PROSPECTIVE OBSERVATIONAL STUDY

Animesh Gupta, Mohammed Hafeez, Sankalp Jagga, Rudresha A.H. et al.
Advances in Clinical Medical Research
Acute Myeloid Leukemia Research
article

CLINICAL OUTCOMES OF ADULT PATIENTS WITH NON-APL ACUTE MYELOID LEUKEMIA TREATED WITH MODIFIED 2+5 INDUCTION CHEMOTHERAPY: A PROSPECTIVE OBSERVATIONAL STUDY

Animesh Gupta, Mohammed Hafeez, Sankalp Jagga, Rudresha A.H., Lokesh K.N., Rajeev
article en

Abstract

Background: Modified induction chemotherapy may be considered in acute myeloid leukemia (AML) when treatment tolerance and toxicity are important clinical concerns. This study evaluated one-year clinical outcomes in patients with non-acute promyelocytic leukemia (non-APL) AML treated with modified 2+5 induction chemotherapy. Materials and Methods: This prospective observational cohort study enrolled 38 consecutive patients with non-APL AML who received modified 2+5 induction chemotherapy at Kidwai Memorial Institute of Oncology, Bengaluru, India, with one-year follow-up. The primary outcome was one-year overall survival (OS). Secondary outcomes were complete remission (CR), one-year progression-free survival (PFS), induction mortality, and treatment-related complications. OS and PFS were summarized using the Kaplan-Meier method; exploratory associations were assessed using the chi-square or Fisher's exact test. Results: CR was achieved in 27 patients (71.1%); 5 (13.2%) had refractory disease, and 6 (15.8%) died during induction before marrow assessment. At one year, 21 patients (55.3%) were alive and 16 (42.1%) were alive without a documented PFS event. Febrile neutropenia was the most common complication (89.5%), followed by culture-positive infection (57.9%) and intensive care unit admission (55.3%). Post-induction remission status was associated with one-year survival and PFS status; as a post-treatment variable unavailable in early deaths, it was not interpreted as a baseline prognostic factor. Conclusion: Modified 2+5 induction chemotherapy resulted in a CR rate of 71.1%; 55.3% of patients were alive at one year and 42.1% were alive without a documented PFS event. Given the small, single-center cohort and absence of a comparator arm, these findings should be considered exploratory.

Advances in Clinical Medical Research
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon